Pharmaceutical - Iressa

Filter

Current filters:

Iressa

Popular Filters

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

Japan Supreme Court absolves AstraZeneca over deaths associated with Iressa

17-04-2013

The Japanese Supreme Court has upheld high court rulings that the Japanese unit of Anglo-Swedish drug…

Asia-PacificAstraZenecaIressaLegalOncologyPharmaceutical

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

NZ's PHARMAC consults on funding for Iressa and Tarceva

31-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

Japan High Court rules in favor of AstraZeneca over Iressa deaths

30-05-2012

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) Japanese subsidiary has received a decision from the…

Asia-PacificAstraZenecaIressaLegalOncologyPharmaceutical

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

European oncologists indicate Tarceva will threaten market position of Iressa in mutated EGFR NSCLC

02-11-2011

According to the majority of surveyed oncologists in the European Union 5 (France, Germany, Italy, Spain…

AstraZenecaEuropeIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Back to top